Unconventional Therapy with IgY in a Psoriatic Mouse Model Targeting Gut Microbiome.
C57 BL/6 mice
IgY
imiquimod
inflammation
psoriatic dermatitis
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
26 Aug 2021
26 Aug 2021
Historique:
received:
04
08
2021
revised:
22
08
2021
accepted:
25
08
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Psoriasis has a multifactorial pathogenesis and recently it was shown that alterations in the skin and intestinal microbiome are involved in the pathogenesis of psoriasis. Therefore, microbiome restoration becomes a promising preventive/therapy strategy in psoriasis. In our pre-clinical study design using a mice model of induced psoriatic dermatitis (Ps) we have tested the proof-of-concept that IgY raised against pathological human bacteria resistant to antibiotics can alleviate psoriatic lesions and restore deregulated immune cell parameters. Besides clinical evaluation of the mice and histology of the developed psoriatic lesions, cellular immune parameters were monitored. Immune cells populations/subpopulations from peripheral blood and spleen cell suspensions that follow the clinical improvement were assessed using flow cytometry. We have quantified T lymphocytes (CD3ε
Identifiants
pubmed: 34575618
pii: jpm11090841
doi: 10.3390/jpm11090841
pmc: PMC8466815
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Competitiveness Operational Program
ID : IntelBiomed project, SMIS code 105631, ID: P_40_197, Grant No. 52/2016
Références
Medicina (Kaunas). 2019 Sep 26;55(10):
pubmed: 31561576
Biotechnol Adv. 2011 Nov-Dec;29(6):860-8
pubmed: 21787857
Skin Pharmacol Physiol. 2013;26(3):119-26
pubmed: 23549156
Br J Dermatol. 2012 Apr;166(4):789-96
pubmed: 22233261
Clin Immunol. 2017 Apr;177:43-49
pubmed: 26477484
Annu Rev Food Sci Technol. 2012;3:163-82
pubmed: 22136128
Acta Derm Venereol. 2019 Feb 1;99(2):226-227
pubmed: 30320869
BMJ. 2020 May 28;369:m1590
pubmed: 32467098
Nat Biotechnol. 2015 Oct;33(10):1103-8
pubmed: 26414350
N Engl J Med. 2009 Jul 30;361(5):496-509
pubmed: 19641206
Front Immunol. 2018 Aug 13;9:1869
pubmed: 30150991
Hum Vaccin Immunother. 2018 Jul 3;14(7):1815-1819
pubmed: 29505317
Theranostics. 2020 Aug 21;10(23):10466-10482
pubmed: 32929360
Drugs Context. 2019 Apr 17;8:212570
pubmed: 31024633
J Immunol. 2017 May 15;198(10):3809-3814
pubmed: 28389592
J Eur Acad Dermatol Venereol. 2019 Mar;33(3):546-552
pubmed: 30242918
J Am Acad Dermatol. 2019 Mar;80(3):714-721
pubmed: 30612986
J Am Acad Dermatol. 2004 Oct;51(4):563-9
pubmed: 15389191
Eur J Nutr. 2014 Apr;53(3):751-9
pubmed: 23999998
Br J Dermatol. 2018 May;178(5):1044-1055
pubmed: 29124739
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
JCI Insight. 2019 Mar 21;4(6):
pubmed: 30747724
Hum Vaccin Immunother. 2013 May;9(5):1039-48
pubmed: 23319156
J Invest Dermatol. 2018 Jan;138(1):e1-e8
pubmed: 29273150
Int J Mol Sci. 2020 Nov 08;21(21):
pubmed: 33171607
J Invest Dermatol. 2013 Feb;133(2):377-85
pubmed: 23014338
Front Immunol. 2020 Feb 21;11:242
pubmed: 32153574
Front Immunol. 2021 Feb 25;12:622306
pubmed: 33717125
Clin Pharmacol Ther. 2020 Feb;107(2):435-442
pubmed: 31502263
J Immunol Res. 2016;2016:4097642
pubmed: 27847830
Biologics. 2008 Mar;2(1):115-24
pubmed: 19707434
Int J Mol Sci. 2019 Feb 10;20(3):
pubmed: 30744173
Pharmaceutics. 2020 Aug 20;12(9):
pubmed: 32825447
N Engl J Med. 2019 Mar 7;380(10):981-983
pubmed: 30855749
Nat Commun. 2016 May 25;7:11724
pubmed: 27222343
Vet Immunol Immunopathol. 2006 Feb 15;109(3-4):209-17
pubmed: 16219363
Drugs Today (Barc). 2010 Apr;46(4):259-64
pubmed: 20502723
Yale J Biol Med. 2020 Mar 27;93(1):97-110
pubmed: 32226340
Clin Dermatol. 2007 Nov-Dec;25(6):606-15
pubmed: 18021899
Br J Dermatol. 2018 Mar;178(3):674-681
pubmed: 28991370
J Eur Acad Dermatol Venereol. 2019 Dec;33(12):2305-2312
pubmed: 31407394
Clin Dermatol. 2018 May - Jun;36(3):376-389
pubmed: 29908580
Front Microbiol. 2018 Jul 10;9:1459
pubmed: 30042740
Front Cell Infect Microbiol. 2019 Feb 04;9:7
pubmed: 30778377
J Eur Acad Dermatol Venereol. 2009 Mar;23(3):288-91
pubmed: 19207651
Exp Dermatol. 2016 Dec;25(12):937-944
pubmed: 27376966
Int J Mol Sci. 2017 Nov 24;18(12):
pubmed: 29186769
PLoS One. 2012;7(8):e42788
pubmed: 22880110
Cell Mol Life Sci. 2018 Jan;75(1):149-160
pubmed: 29124307
Lancet. 2014 Dec 6;384(9959):2036-45
pubmed: 25127208
Expert Rev Clin Immunol. 2015;11(11):1177-88
pubmed: 26428036
Drugs Context. 2019 Jul 09;8:212594
pubmed: 31391856
Ther Clin Risk Manag. 2008 Apr;4(2):345-51
pubmed: 18728850
Exp Ther Med. 2020 Jul;20(1):151-158
pubmed: 32536989
J Med Chem. 2018 Dec 27;61(24):10976-10995
pubmed: 30010338
Exp Ther Med. 2019 Feb;17(2):1030-1038
pubmed: 30679970
J Invest Dermatol. 2020 Aug;140(8):1546-1555.e4
pubmed: 31972249
Front Microbiol. 2019 Apr 24;10:887
pubmed: 31105675
Exp Ther Med. 2019 Dec;18(6):4956-4966
pubmed: 31798717
J Dermatol. 2015 Feb;42(2):166-70
pubmed: 25510344
Front Microbiol. 2020 Dec 15;11:589726
pubmed: 33384669
Int J Mol Sci. 2021 Feb 03;22(4):
pubmed: 33546306
Nat Rev Drug Discov. 2017 Dec;16(12):843-862
pubmed: 29104284
Psoriasis (Auckl). 2016 May 27;6:65-71
pubmed: 29387595
Acta Derm Venereol. 2009;89(5):492-7
pubmed: 19734975
J Immunol. 2009 May 1;182(9):5836-45
pubmed: 19380832